Breast Cancer Advice. Keep up to date with the latest information and treatment of breast cancer.
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

Radiation Not Needed in Many Older Breast Cancer Patients

No added benefit over surgery plus tamoxifen alone in those 70-plus with early stage disease, study finds

FRIDAY, May 21 (HealthDay News) -- A new study provides more support for the idea of allowing women aged 70 and older with early stage breast cancer to avoid radiation treatment if they have undergone a lumpectomy and treatment with the drug tamoxifen.

"The standard of care for women 70 and older with very small tumors that are estrogen-positive and node-negative -- the largest group of breast cancer patients in this age group -- had been lumpectomy and radiation," study lead author Dr. Kevin Hughes, co-director of the Avon Comprehensive Breast Evaluation Center at Massachusetts General Hospital in Boston, said in a news release.

Advertisement
Related Stories
 border=
Nearly 900,000 Fewer Cancer Deaths Since 1990: Report
FDA Approves Test That Spots Aggressive Breast Cancer
Women in Their 40s Want Mammograms: Poll
Related Videos
 border=
Tumor Detecting App: Medicine's Next Big Thing?
Powerful Combo Reducing Lymphedema
Fighting Breast Cancer on Your Lunch Break
Related Slides
 border=
Breast Cancer
Breast Self-Exam


"Earlier reports of this study with shorter median follow-up have shown the risk of recurrence without radiation to be only marginally worse than with radiation, but there was concern that longer follow-up would show a blossoming of recurrences," he said. "This study confirms that for older women with early stage breast cancer, lumpectomy without radiation is a viable alternative, and tamoxifen may replace the need for radiation."

It has been standard for younger women with early stage breast cancer to receive radiation therapy after a lumpectomy.

The researchers reached their conclusions after randomly assigning 636 women with early stage breast cancer -- all 70 or older -- to receive tamoxifen (319 patients), or tamoxifen plus radiation (317 patients).

After a median follow-up of more than 10 years, the researchers found that the risk of recurrence was lower among those who received both treatments (2 percent) compared with those who received the drug alone (8 percent). But the two groups didn't differ significantly in terms of overall survival and risk of dying from breast cancer.

The findings were released May 20 and the study is to be presented at the annual meeting of the American Society of Clinical Oncology, June 4 to 8 in Chicago.

More information

For more about breast cancer, visit BreastCancer.org .

-- Randy Dotinga

SOURCE: American Society of Clinical Oncology, news release, May 20, 2010

Copyright © 2010 HealthDay. All rights reserved.
Last updated 5/21/2010



Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.


Feb 5, 2012
Home
Search
Powered By HealthLine
New! For timely and trustworth health information, expert advice and much more, visit Breast Cancer Connection
Patient Guide
News
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Newsletters
Privacy Policy
Terms of Use

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service  

To find more information on specific conditions, please visit our partner sites: